Antiva Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Antiva Biosciences Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11257
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Antiva Biosciences Inc (Antiva) formerly Hera Therapeutics Inc, is a clinical stage bio-pharmaceutical company focused on the development of novel medicines for the treatment of diseases caused by human papillomavirus (HPV) infection. Its lead product candidate ABI-1968, is a double prodrug of an acyclic nucleoside phosphonate which blocks HPV replication and inducing apoptosis in HPV-infected lesions, without affecting normal cells. Antiva is developing additional molecules based on its anti-viral platform targeting HIV infection, the herpes virus, cytomegalovirus, cervical dysplasia, vulvar intraepithelial neoplasia (VIN), among others. The company is funded by Brace Pharma Capital, Canaan Partners, Lumira Capital Corp, and others. Antiva Biosciences is headquartered in South San Francisco, California, the US.

Antiva Biosciences Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Antiva Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Antiva Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Antiva Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Antiva Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Antiva Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Antiva Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Antiva Biosciences Raises USD15 Million in Series C-1 Financing 10
Antiva Biosciences Raises USD22 Million in Series C Financing 12
Antiva Biosciences Raises USD14.7 Million in Venture Financing 13
Antiva Biosciences Raises USD16 Million in Series B Financing 14
Hera Therapeutics Raises USD9 Million in Venture Financing 15
Hera Therapeutics Raises USD1 Million in Venture Financing 16
Hera Therapeutics Raises US$1 Million In Venture Financing 17
Hera Therapeutics Raises USD0.5 Million in Venture Financing 18
Equity Offering 19
Antiva Biosciences Spin Out from University of California San Diego 19
Antiva Biosciences Inc – Key Competitors 20
Antiva Biosciences Inc – Key Employees 21
Antiva Biosciences Inc – Locations And Subsidiaries 22
Head Office 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Antiva Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts 2
Antiva Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Antiva Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Antiva Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Antiva Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Antiva Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Antiva Biosciences Raises USD15 Million in Series C-1 Financing 10
Antiva Biosciences Raises USD22 Million in Series C Financing 12
Antiva Biosciences Raises USD14.7 Million in Venture Financing 13
Antiva Biosciences Raises USD16 Million in Series B Financing 14
Hera Therapeutics Raises USD9 Million in Venture Financing 15
Hera Therapeutics Raises USD1 Million in Venture Financing 16
Hera Therapeutics Raises US$1 Million In Venture Financing 17
Hera Therapeutics Raises USD0.5 Million in Venture Financing 18
Antiva Biosciences Spin Out from University of California San Diego 19
Antiva Biosciences Inc, Key Competitors 20
Antiva Biosciences Inc, Key Employees 21

List of Figures
Antiva Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Antiva Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Antiva Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Antiva Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Antiva Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Antiva Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Antiva Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Antiva Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Antiva Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Clinuvel Pharmaceuticals Ltd (CUV):企業の財務・戦略的SWOT分析
    Clinuvel Pharmaceuticals Ltd (CUV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Galp Energia SGPS SA (GALP)-エネルギー分野:企業M&A・提携分析
    Summary Galp Energia SGPS S.A. (Galp Energia) is an integrated oil and natural gas company. It explores for, develops and produces crude oil and natural gas; refines crude oil and markets refined petroleum products. The company also imports, transports and distributes natural gas. It conducts the na …
  • Aminex PLC (AEX):企業の財務・戦略的SWOT分析
    Summary Aminex PLC (Aminex) is an oil and gas company that explores, develops and produces oil and gas reserves in Africa. The company provides assets such as Valeni field and Viktorovka field in Moldova; West Esh el Mellaha-2 in Egypt; and Kiliwani North development, Nyuni exploration, and Ruvuma e …
  • Gene Techno Science Co Ltd (4584):企業の財務・戦略的SWOT分析
    Summary Gene Techno Science Co Ltd (GTS) develops and markets drug and antibodies for intractable diseases, cancer, and rare diseases. The company develops biological, biosimilar and regenerative medicine in the therapy areas of renal disease, immunological, oncology, ophthalmic, and bone related di …
  • Tokyo Gas Co., Ltd.:企業の戦略・SWOT・財務分析
    Tokyo Gas Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tokyo Gas Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • OP Financial Group:企業の戦略・SWOT・財務分析
    OP Financial Group - Strategy, SWOT and Corporate Finance Report Summary OP Financial Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • KfW Group:企業の戦略・SWOT・財務分析
    KfW Group - Strategy, SWOT and Corporate Finance Report Summary KfW Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Shionogi & Co., Ltd.:企業の戦略・SWOT・財務情報
    Shionogi & Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shionogi & Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Pakistan International Airlines Corporation:企業の戦略・SWOT・財務分析
    Pakistan International Airlines Corporation - Strategy, SWOT and Corporate Finance Report Summary Pakistan International Airlines Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Georgia Power Co (GPW)-エネルギー分野:企業M&A・提携分析
    Summary Georgia Power Company (Georgia Power), a subsidiary of the Southern Power Company, generates, transmits, distributes and sells electricity. The company produces electricity using various sources of energy such as coal, nuclear, solar, gas and hydro. It supplies electricity in Georgia and to …
  • Phoenix Global Resources Plc (PGR):企業の財務・戦略的SWOT分析
    Phoenix Global Resources Plc (PGR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • The Dai-ichi Life Insurance Co Ltd:戦略・SWOT・企業財務分析
    The Dai-ichi Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report Summary The Dai-ichi Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Pulsion Medical Systems SE (PUS):医療機器:M&Aディール及び事業提携情報
    Summary Pulsion Medical Systems SE (Pulsion Medical Systems), formerly Pulsion Medical Systems AG, a subsidiary of Getinge AB, is a medical device company that manufactures and develops critical care systems and monitors. The company’s products include ProAQT sensor, PiCCO catheter, CeVOX module, Pi …
  • Henry Ford Health System:企業の戦略的SWOT分析
    Henry Ford Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • The Jones Financial Companies, L.L.L.P.:企業の戦略的SWOT分析
    The Jones Financial Companies, L.L.L.P. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Acorda Therapeutics Inc (ACOR):企業の財務・戦略的SWOT分析
    Acorda Therapeutics Inc (ACOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Centre for Drug Research and Development:製薬・医療:M&Aディール及び事業提携情報
    Summary Centre for Drug Research and Development (CDRD) is a drug development and commercialization center that provides scientific infrastructure to transform discoveries into innovative therapeutic products and improved health outcomes. The center's drug development platform includes target valida …
  • Hutchinson SA:企業の戦略的SWOT分析
    Hutchinson SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Natrix Separations Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Natrix Separations Inc (Natrix), formerly Nysa Membrane Technologies, a subsidiary of Merck KGaA, is a supplier of single use and multi-cycle disposable chromatography products. The company offers NatriFlo HD-Q membrane adsorbers, an advanced material with a three-dimensional macroporous hyd …
  • Canon USA Inc-医療機器分野:企業M&A・提携分析
    Summary Canon U.S.A. Inc (Canon), a subsidiary of Canon Inc, is a technology company that designs, develops and commercializes imaging equipment and information systems, and digital imaging solutions. The company offers products which include cameras and camcorders, lenses, flashes and binoculars, o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆